- The national campaign seeks to emphasize the unbearable burden ALGS has on patients and their families. - Mirum underscores its commitment to continued understanding of the rare liver disease through research and support of ALGS community. FOSTER CITY, Calif. --(BUSINESS WIRE)--Jan.

FOSTER CITY, Calif. --(BUSINESS WIRE)--Jan. 14, 2021-- Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today announced that the first patient has been enrolled in Mirum’s Phase 2b VISTAS study evaluating volixibat in adult patients with primary sclerosing cholangitis (PSC), an idiopathic chronic

- Completion of maralixibat rolling NDA targeted for Q1 2021 - Expecting first-patient-in for volixibat studies in ICP and PSC, and maralixibat study in biliary atresia in Q1 2021 - Launching volixibat primary biliary cholangitis program in H2 2021 - European commercial leader hired in anticipation

FOSTER CITY, Calif. --(BUSINESS WIRE)--Jan. 8, 2021-- Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), a biopharmaceutical company focused on the development and commercialization of a late-stage pipeline of novel therapies for debilitating liver diseases, today announced that on January 8, 2021 , the

FOSTER CITY, Calif. --(BUSINESS WIRE)--Jan. 4, 2021-- Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today announced that it will present at the annual J.P. Morgan Healthcare Conference taking place virtually January 11-14, 2021 . Chris Peetz , Mirum’s president and chief executive officer, will